LONGMONT, CO--(Marketwired - May 2, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to announce that Pamela Clum has joined the newly formed Advisory Board of the Company.
Since 2002, Pamela Clum has been the chief product formulator, developer, and marketer of the unique "Canna-mist" brand of sublingual cannabinoid (CBD) spray which is now part of MediJane's portfolio of products exclusively licensed from Phoenix Bio Pharmaceuticals Corporation. Ms. Clum is the co-author of "Ecophysiology of Short Rotation Forest Crops" and has presented botany focused research abstracts at several scientific conferences. Pamela holds a Master of Science degree in Botany from the University of Washington.
"Pamela's addition to the MediJane Advisory Board will provide our company with access to remarkable insights from an industry pioneer in the medical cannabis sector," commented Ronald Lusk, CEO of MediJane Holdings Inc. "Her extensive experience and understanding of formulating and developing innovative delivery systems, and her particular familiarity with our Canna-mist product make her an invaluable source of industry knowledge going-forward."
Pamela Clum concluded, "I'm very excited to join the MediJane Advisory Board. I'm looking forward to contributing my experience to support an emerging, expanding, and fast-moving industry. I hope to assist MediJane in many aspects of business development such as formulations, outsourcing, branding, manufacturing, and anywhere else we feel my skills can have a positive impact."
About MediJane Holdings Inc. (MJMD)
MediJane Holdings Inc. (MJMD) is in the business of marketing and distributing products within the medical marijuana industry, including transdermal patches, capsules, sublingual sprays, and other medical delivery systems. With sales offices opening in California and Colorado, and a planned expansion into a national footprint, MediJane products are designed to give doctors the ability to provide patients accurate and effective doses of cannabinoids to manage and treat pain and other specific illnesses. MediJane's lead product is an innovative non-drowsy "Daytime Pain plus CBD" oral capsule for the treatment of inflammation and chronic, neuropathic, arthritic, and back pain. This smokeless and accurate dose alternative is MediJane's initial launch into the chronic pain management market, which is estimated at over $45 billion annually in North America.
For more information, visit www.medijane.co
Disclaimer/Safe Harbor: Some information in this MediJane Holdings Inc. (MJMD) press release constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause MJMD's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to MJMD herein are expressly qualified in their entirety by the above-mentioned cautionary statement. MJMD disclaims any obligation to update forward-looking statements contained in this press release, except as may be required by law.